COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPS COMPASS Pathways plc

Market Closed 12-12 16:00:00 EST

6.74

-0.20

-2.88%

盘后6.76

+0.02+0.34%

19:56 EST

High7.13	Low6.69	Vol1.85M
Open7.01	D1 Closing6.94	Amplitude6.34%
Mkt Cap647.15M	Tradable Cap393.71M	Total Shares96.02M
T/O12.80M	T/O Rate3.17%	Tradable Shares58.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPS","market":"US","secType":"STK","nameCN":"COMPASS Pathways plc","latestPrice":6.74,"timestamp":1765573200000,"preClose":6.94,"halted":0,"volume":1854605,"hourTrading":{"tag":"盘后","latestPrice":6.7628,"preClose":6.74,"latestTime":"19:56 EST","volume":517333,"amount":3486742.6306,"timestamp":1765587382851},"delay":0,"floatShares":58414107,"shares":96017044,"eps":-2.73668,"marketStatus":"Market Closed","change":-0.2,"latestTime":"12-12 16:00:00 EST","open":7.01,"high":7.13,"low":6.69,"amount":12800105.37058,"amplitude":0.063401,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.73668,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":6.94,"preHourTrading":{"tag":"盘前","latestPrice":7,"preClose":6.94,"latestTime":"09:29 EST","volume":11612,"amount":79355.722892,"timestamp":1765549755070},"postHourTrading":{"tag":"盘后","latestPrice":6.7628,"preClose":6.74,"latestTime":"19:56 EST","volume":517333,"amount":3486742.6306,"timestamp":1765587382851},"volumeRatio":1.045299221044714,"impliedVol":0.8407,"impliedVolPercentile":0.096},"requestUrl":"/m/hq/s/CMPS/wiki","defaultTab":"wiki","newsList":[{"id":"2590348982","title":"Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348982?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279818,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will host a webinar on January 7, 2026, from 10:00 to 11:30 am ET to discuss the company's commercial preparations for treatment-resistant depression  and clinical trial plans for post-traumatic stress disorder . The event will feature perspectives from key opinion leaders and industry experts on the current treatment landscape and unmet needs in TRD and PTSD. The company's management will also review commercial readiness for COMP360 in TRD and outline plans for a late-stage clinical program in PTSD. The webinar will be available via live audio webcast, with a replay accessible for 30 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9971LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2590348528","title":"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590348528?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:30","pubTimestamp":1765279800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA5TTMKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2584135581","title":"Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135581","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584135581?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:30","pubTimestamp":1763638218,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, at 10:00am ET on December 2, 2025. The company will also join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY, at 1:30pm ET on December 3, 2025. Live audio webcasts of both events will be available on the Compass website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL6TV3Hg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","PIPR","BK4139","CMPS","EVR"],"gpt_icon":0},{"id":"2581708946","title":"Compass Pathways Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2581708946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581708946?lang=en_us&edition=fundamental","pubTime":"2025-11-06 02:14","pubTimestamp":1762366440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 13:14 ET (18:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2581779191","title":"RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779191?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:55","pubTimestamp":1762354536,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2581072681","title":"Compass Pathways to Participate in Stifel 2025 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072681","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072681?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:30","pubTimestamp":1762342234,"startTime":"0","endTime":"0","summary":"Compass Pathways plc will participate in the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11, 2025. Management will present at 10:40 am ET, with a live audio webcast available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLH5VW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"1153232989","title":"Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1153232989","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153232989?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:28","pubTimestamp":1762306135,"startTime":"0","endTime":"0","summary":"Shares of Compass Pathways PLC (CMPS) plummeted 5.28% in Tuesday's trading session following the release of its third-quarter financial results. The clinical-stage mental health care company reported...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CMPS"],"gpt_icon":0},{"id":"2580267756","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, Metsera","url":"https://stock-news.laohu8.com/highlight/detail?id=2580267756","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580267756?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:47","pubTimestamp":1762271240,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, Hertz Global, MetseraEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL6N3WG1MI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQT","SWK","LU0545039389.USD","NEM","HSIC","SRPT","SPOT","EXAS","HOG","FCX","LU0055631609.USD","LU1582987597.SGD","STRK","ETN","XOM","VSCO","IHRT","LU0471298694.HKD","CPRI",".IXIC","CEG","YUM","CMPS","WING","TSYW.SI","LHX","CMS","EXC","HTZ","WAT","CVX","CTRA","SCCO","ADM","NCLH","HIMS","MPC","MTSR","ZTS"],"gpt_icon":1},{"id":"2580758760","title":"Compass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2580758760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580758760?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:32","pubTimestamp":1762266726,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC reports results for the quarter ended September 30 - Earnings SummaryCompass Pathways PLC CMPS.OQ reported a quarterly adjusted loss of $1.44 per share for the quarter ended Septe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG208:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2580758923","title":"Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2580758923","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580758923?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:31","pubTimestamp":1762266663,"startTime":"0","endTime":"0","summary":"Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression  and post-traumatic stress disorder . The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo . Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL1QSMfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2580673902","title":"BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2580673902","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580673902?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:48","pubTimestamp":1762260481,"startTime":"0","endTime":"0","summary":"BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug** Shares of drug developer Compass Pathways CMPS.O rise 12.4% to $6.69 premarket** Co says it is moving up its commercial launch plans for its experimental depression treatment COMP360, by up to a year, following a positive meeting with the U.S. FDA** CMPS's COMP360 is being developed for people with treatment-resistant depression** Co now expects to release key data from its ongoing clinical trials in early 2026, as well as additional results from late-stage trials ** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says** Up to last close, stock up ~57% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL4N3WG1A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2580738265","title":"Biotech firm Compass Pathways' operating income beats Q3 analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2580738265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580738265?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:47","pubTimestamp":1762256849,"startTime":"0","endTime":"0","summary":"Biotech firm Compass Pathways' operating income beats Q3 analyst expectationsOverviewCompass Pathways Q3 net loss driven by non-cash warrant liabilities adjustmentCompany accelerates COMP360 commercia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"1137127127","title":"Stock Track | COMPASS Pathways Soars 11.60% Pre-market on Accelerated Commercialization Plans for COMP360","url":"https://stock-news.laohu8.com/highlight/detail?id=1137127127","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137127127?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:32","pubTimestamp":1762255957,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc (CMPS) stock surged 11.60% in pre-market trading on Tuesday following the announcement of its third-quarter 2025 financial results and the acceleration of commercialization plans...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CMPS"],"gpt_icon":0},{"id":"2580780498","title":"Compass Pathways Q3 EPS $(1.44) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780498","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780498?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:31","pubTimestamp":1762255872,"startTime":"0","endTime":"0","summary":"Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.44) per share which missed the analyst consensus estimate of $(0.38) by 278.95 percent. This is a 157.14 percent decrease over losses of $(0.56) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48615359/compass-pathways-q3-eps-1-44-misses-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","CMPS","NQmain","USJW.SI","TQQQ","QID","NVIW.SI",".IXIC","QLD","MNQmain","USAW.SI","PSQ","SQQQ","BK4139"],"gpt_icon":0},{"id":"2580780181","title":"BRIEF-COMPASS Pathways Q3 EPS USD -1.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780181","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780181?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255847,"startTime":"0","endTime":"0","summary":"BRIEF-COMPASS Pathways Q3 EPS USD -1.44\n\n\nNov 04 (Reuters) - COMPASS Pathways Q3 operating expenses USD 40.536 million.\n\nQ3 net income USD -137.717 million\nQ3 pretax profit USD -137.947 million\nQ3 operating income USD -40.536 million vs. IBES estimate USD -42.7 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX9CFF31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2580078097","title":"Compass Pathways reports Q3 2025 results with cash position of $185.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580078097","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580078097?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255847,"startTime":"0","endTime":"0","summary":"Compass Pathways plc reported a cash and cash equivalents position of $185.9 million as of September 30, 2025, up from $165.1 million at December 31, 2024. Debt stood at $31.3 million, compared to $30.2 million at year-end 2024. Research and development expenses for the nine months ended September 30, 2025, were $88.5 million, a slight increase from $86.9 million in the same period of 2024, mainly due to expenses related to late-stage COMP360 phase 3 clinical trials. The company expects full year 2025 net cash used in operating activities to be between $120 million and $145 million, and anticipates its cash position will fund operations into 2027. Compass Pathways is accelerating its commercialization plans for COMP360 in treatment-resistant depression by 9-12 months, following the completion of COMP006 trial enrollment and positive discussions with the FDA regarding NDA submission strategies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL8r5Kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2580780567","title":"Compass Pathways: Accelerating Commercialization Readiness Plans for Comp360 by 9-12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780567?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nP8N3LY040:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2580780106","title":"Compass Pathways: Disclosure of 26-Week (Part B) Comp006 Data Expected in Early Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780106?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nP8N3LY040:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","BK4139"],"gpt_icon":0},{"id":"2580681780","title":"Compass Pathways Q3 Pretax Profit USD -137.947 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580681780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580681780?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX9CFF31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2580780705","title":"Press Release: Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780705?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:30","pubTimestamp":1762255800,"startTime":"0","endTime":"0","summary":"--  Company accelerating commercialization readiness plans by 9-12 months,following completion of COMP006 trial enrollment and positive meeting. with FDA on NDA submission strategies for COMP360 in TRD, including. --  Company now plans to disclose 9-week data  from COMP006. --  Disclosure of 26-week  COMP006 data expected in early Q3 2026. Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business.\"With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months,\" said Kabir Nath, Chief Executive Officer at Compass Pathways. \"We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the me","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasspathways.com","stockEarnings":[{"period":"1week","weight":0.1581},{"period":"1month","weight":0.1502},{"period":"3month","weight":0.2962},{"period":"6month","weight":0.5353},{"period":"1year","weight":0.5283},{"period":"ytd","weight":0.7831}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.070712},{"month":2,"riseRate":0.2,"avgChangeRate":-0.087169},{"month":3,"riseRate":0.2,"avgChangeRate":-0.109959},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016443},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043784},{"month":6,"riseRate":0.6,"avgChangeRate":-0.018137},{"month":7,"riseRate":0.8,"avgChangeRate":0.262657},{"month":8,"riseRate":0.4,"avgChangeRate":-0.005792},{"month":9,"riseRate":0.2,"avgChangeRate":-0.10118},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.009194},{"month":11,"riseRate":0.333333,"avgChangeRate":0.034765},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.016435}],"exchange":"NASDAQ","name":"COMPASS Pathways plc","nameEN":"COMPASS Pathways plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"COMPASS Pathways plc,CMPS,COMPASS Pathways plc股票,COMPASS Pathways plc股票老虎,COMPASS Pathways plc股票老虎国际,COMPASS Pathways plc行情,COMPASS Pathways plc股票行情,COMPASS Pathways plc股价,COMPASS Pathways plc股市,COMPASS Pathways plc股票价格,COMPASS Pathways plc股票交易,COMPASS Pathways plc股票购买,COMPASS Pathways plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction